Premium
Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long‐Term Extension Studies
Author(s) -
Gladman Dafna D.,
CharlesSchoeman Christina,
McInnes Iain B.,
Veale Douglas J.,
Thiers Bruce,
Nurmohamed Mike,
Graham Dani,
Wang Cunshan,
Jones Thomas,
Wolk Robert,
DeMasi Ryan
Publication year - 2019
Publication title -
arthritis care and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.032
H-Index - 163
eISSN - 2151-4658
pISSN - 2151-464X
DOI - 10.1002/acr.23930
Subject(s) - tofacitinib , medicine , psoriatic arthritis , blood pressure , adverse effect , mace , population , gastroenterology , arthritis , rheumatoid arthritis , myocardial infarction , environmental health , conventional pci
Objective The risk of cardiovascular disease ( CVD ) is higher in patients with psoriatic arthritis (PsA) compared to the general population. Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA. Because tofacitinib increases circulating lipid levels in some patients, we evaluated CVD risk factors and major adverse cardiovascular events ( MACE ) in patients with active PsA receiving tofacitinib 5 or 10 mg twice daily plus conventional synthetic disease‐modifying antirheumatic drugs. Methods Data were pooled from 2 phase III studies (Efficacy and Safety of Tofacitinib in Psoriatic Arthritis [ OPAL Broaden] and Tofacitinib in Patients with Psoriatic Arthritis With Inadequate Response to TNF Inhibitors [ OPAL Beyond]) and 1 ongoing long‐term extension (Open‐Label Extension Study of Tofacitinib in Psoriatic Arthritis [ OPAL Balance], data cutoff January 2017; database not locked). Outcomes included fasting lipid levels, blood pressure, hypertension‐related adverse events ( AE s; including hypertension, high blood pressure, and increased blood pressure), and MACE . Results Overall, 783 tofacitinib‐treated patients were included. Percentage increases from baseline in low‐density lipoprotein cholesterol (LDL‐c) and high‐density lipoprotein cholesterol (HDL‐c) levels ranged from 9% to 14% for tofacitinib 5 mg and 10 mg at 3 and 6 months; no meaningful changes in LDL ‐c: HDL ‐c or total cholesterol: HDL ‐c ratios were observed. Blood pressure remained stable for 24 months. Fifty‐eight patients (7.4%) had hypertension‐related AE s; none were fatal (incidence rate [ IR ] per 100 patient‐years 4.81 [95% confidence interval (95% CI ) 3.65–6.22]). Five patients (0.6%) had MACE (IR 0.24 [95% CI 0.05–0.70]); 2 were fatal. Conclusion Serum lipid level increases at month 3 following tofacitinib treatment in PsA were consistent with observations in rheumatoid arthritis and psoriasis. The IR of hypertension‐related AE s and MACE was low; long‐term follow‐up is ongoing.